Overview

CytoSorbents Investor Relations

CytoSorbents is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, with >270,000 CytoSorb devices sold in 70+ countries to date, and with applications to FDA and Health Canada for DrugSorb-ATR marketing approval under review.

Featured News

CytoSorbents

Press Release

30 Oct '25

CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights

PRINCETON, N.J., Oct. 30, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2025 financial results and recent business highlights after the market close on Thursday, November 13, 2025. CytoSorbents’ management will host a ... CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights

29 Sep '25

CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen

PRINCETON, N.J., Sept. 29, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today its strong scientific presence at the upcoming European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting, the world’s largest gathering for the global cardiothoracic ... CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen

16 Sep '25

CytoSorbents Provides DrugSorb-ATR Regulatory Update

PRINCETON, N.J., Sept. 16, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today provided a regulatory update on DrugSorb™-ATR. On August 20, 2025, the Company announced that it had received a U.S. Food and Drug Administration (FDA) appeal decision ... CytoSorbents Provides DrugSorb-ATR Regulatory Update

08 Sep '25

CytoSorbents To Host Global Webinar on “Turning the Tide in Sepsis and Septic Shock: Real World Insights with CytoSorb” in Recognition of World Sepsis Day

PRINCETON, N.J., Sept. 8, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, details its upcoming World Sepsis Day Global Webinar, entitled, “Turning the Tide in Sepsis and Septic Shock: Real World Insights with CytoSorb” to be held ... CytoSorbents To Host Global Webinar on “Turning the Tide in Sepsis and Septic Shock: Real World Insights with CytoSorb” in Recognition of World Sepsis Day

View All News